Reuters logo
BRIEF-Kubota Pharmaceutical Holdings unit gets orphan drug designation from FDA for treatment of stargardt disease
January 6, 2017 / 6:28 AM / a year ago

BRIEF-Kubota Pharmaceutical Holdings unit gets orphan drug designation from FDA for treatment of stargardt disease

Jan 6 (Reuters) - Kubota Pharmaceutical Holdings Co Ltd :

* Says its unit Acucela Inc announced that the FDA (U.S. Food and Drug Administration) granted orphan drug designation to Acucela’s leading drug candidate emixustat hydrochloride(“emixustat”) for the treatment of stargardt disease

Source text in Japanese: goo.gl/jLgyqA

Further company Coverage: (Beijing Headline News)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below